Diabetes mellitus represents a key cardiometabolic comorbidity of particular interest in patients with inflammatory bowel disease (IBD), given the shared pathways of insulin resistance and systemic inflammation with metabolic dysfunction-associated steatotic liver disease (MASLD). This evidence concerns the gene INS and inflammatory bowel disease.